Adverum Biotechnologies (NASDAQ: ADVM) and Summit Therapeutics (NASDAQ:SMMT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.
Institutional and Insider Ownership
30.1% of Adverum Biotechnologies shares are owned by institutional investors. Comparatively, 29.3% of Summit Therapeutics shares are owned by institutional investors. 7.8% of Adverum Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares Adverum Biotechnologies and Summit Therapeutics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Adverum Biotechnologies||$1.46 million||112.60||-$113.74 million||($1.50)||-2.43|
|Summit Therapeutics||$2.90 million||53.45||-$28.59 million||($0.10)||-112.00|
Summit Therapeutics has higher revenue and earnings than Adverum Biotechnologies. Summit Therapeutics is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current ratings for Adverum Biotechnologies and Summit Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Adverum Biotechnologies currently has a consensus price target of $4.75, indicating a potential upside of 30.14%. Summit Therapeutics has a consensus price target of $22.67, indicating a potential upside of 102.38%. Given Summit Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Adverum Biotechnologies.
This table compares Adverum Biotechnologies and Summit Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Adverum Biotechnologies has a beta of 2.44, meaning that its share price is 144% more volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500.
Summit Therapeutics beats Adverum Biotechnologies on 9 of the 14 factors compared between the two stocks.
About Adverum Biotechnologies
Adverum Biotechnologies, Inc., formerly Avalanche Biotechnologies, Inc., is a gene therapy company. The Company is engaged in discovering and developing medicines to patients suffering from chronic or debilitating disease. The Company operates and manages its business in the segment of developing and commercializing gene therapeutics. It focuses on diseases with unmet medical need, including ophthalmic diseases, such as wet age-related macular degeneration (AMD), as well as rare genetic diseases. The Company’s product candidates include AVA-101 and AVA-201 for treatment of Wet AMD; AVA-322 and AVA-323 for the treatment of Color Vision Deficiency, and AVA-311 for the treatment of Juvenile X-linked Retinoschisis. It has generated human proof-of-concept data for AVA-101 in a Phase I trial with over eight wet AMD subjects conducted at Lions Eye Institute (LEI) in Australia. It is developing AVA-322 and AVA-323 for the treatment of color vision deficiency (CVD).
About Summit Therapeutics
Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Its lead DMD product candidate is ezutromid, which is an orally administered small molecule. Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid. Its DMD program is based on utrophin modulation. It has received an orphan drug designation to ezutromid for the treatment of DMD. It is also developing an earlier-stage pipeline of second and future generation utrophin modulators for the treatment of DMD.
Receive News & Ratings for Adverum Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adverum Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.